bioAffinity Technologies annual r&d spending
2021
2022
2023
2024
2025
bioAffinity Technologies R&D Spending Growth & History (BIAF)
bioAffinity Technologies's r&d spending was $1.4M for fiscal 2025.
View full bioAffinity Technologies company overviewbioAffinity Technologies annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.4M | −$77,868 | −5.33% |
| 2024 | 2024-12-31 | $1.5M | −$6,709 | −0.46% |
| 2023 | 2023-12-31 | $1.5M | $89,312 | +6.48% |
| 2022 | 2022-12-31 | $1.4M | $371,148 | +36.84% |
| 2021 | 2021-12-31 | $1.0M | — | — |
bioAffinity Technologies quarterly r&d spending
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $361,575 | $50,203 | +16.12% |
| Q1 2026 | 2026-03-31 | $349,707 | −$17,679 | −4.81% |
| Q4 2025 | 2025-12-31 | $374,012 | −$16,646 | −4.26% |
| Q3 2025 | 2025-09-30 | $330,589 | $56,092 | +20.43% |
| Q2 2025 | 2025-06-30 | $311,372 | −$91,061 | −22.63% |
| Q1 2025 | 2025-03-31 | $367,386 | −$26,253 | −6.67% |
| Q4 2024 | 2024-12-31 | $390,658 | −$42,160 | −9.74% |
| Q3 2024 | 2024-09-30 | $274,497 | −$55,879 | −16.91% |
| Q2 2024 | 2024-06-30 | $402,433 | $67,308 | +20.08% |
| Q1 2024 | 2024-03-31 | $393,639 | $24,022 | +6.50% |
| Q4 2023 | 2023-12-31 | $432,818 | −$97,795 | −18.43% |
| Q3 2023 | 2023-09-30 | $330,376 | $10,632 | +3.33% |
| Q2 2023 | 2023-06-30 | $335,125 | $86,706 | +34.90% |
| Q1 2023 | 2023-03-31 | $369,617 | $89,769 | +32.08% |
| Q4 2022 | 2022-12-31 | $530,613 | — | — |
| Q3 2022 | 2022-09-30 | $319,744 | −$11,028 | −3.33% |
| Q2 2022 | 2022-06-30 | $248,419 | — | — |
| Q1 2022 | 2022-03-31 | $279,848 | — | — |
| Q3 2021 | 2021-09-30 | $330,772 | — | — |
bioAffinity Technologies r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, bioAffinity Technologies's r&d spending increased from $1.0M to $1.4M, a change of $375,883. The latest reported quarter, Q2 2026, shows $361,575.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review bioAffinity Technologies source filings ↗